Hester Biosciences Limited (NSE:HESTERBIO) — Market Cap & Net Worth
Market Cap & Net Worth: Hester Biosciences Limited (HESTERBIO)
Hester Biosciences Limited (NSE:HESTERBIO) has a market capitalization of $201.99 Million (Rs18.68 Billion) as of September 19, 2026. Listed on the NSE stock exchange, this India-based company holds position #16602 globally and #856 in its home market, demonstrating a -5.47% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hester Biosciences Limited's stock price Rs2195.60 by its total outstanding shares 8506865 (8.51 Million). Also see how large is Hester Biosciences Limited's balance sheet for a full breakdown of the balance sheet.
Hester Biosciences Limited Market Cap History: 2015 to 2026
Hester Biosciences Limited's market capitalization history from 2015 to 2026. Data shows growth from $48.98 Million to $201.99 Million (12.12% CAGR). Also see Hester Biosciences Limited cash conversion from operations for how efficiently the company converts equity into cash flow.
Hester Biosciences Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hester Biosciences Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check HESTERBIO share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.05x
Hester Biosciences Limited's market cap is 0.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.54x
Hester Biosciences Limited's market cap is 0.54 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $63.36 Million | $1.01 Billion | $188.83 Million | 0.06x | 0.34x |
| 2017 | $165.31 Million | $1.23 Billion | $234.48 Million | 0.13x | 0.71x |
| 2018 | $101.44 Million | $1.36 Billion | $256.21 Million | 0.07x | 0.40x |
| 2019 | $130.76 Million | $1.78 Billion | $415.67 Million | 0.07x | 0.31x |
| 2020 | $154.74 Million | $1.83 Billion | $291.71 Million | 0.08x | 0.53x |
| 2021 | $230.27 Million | $2.14 Billion | $344.30 Million | 0.11x | 0.67x |
| 2022 | $163.67 Million | $2.35 Billion | $393.20 Million | 0.07x | 0.42x |
| 2023 | $133.80 Million | $2.66 Billion | $266.27 Million | 0.05x | 0.50x |
| 2024 | $220.74 Million | $3.05 Billion | $188.89 Million | 0.07x | 1.17x |
| 2025 | $147.17 Million | $3.11 Billion | $274.88 Million | 0.05x | 0.54x |
Competitor Companies of HESTERBIO by Market Capitalization
Companies near Hester Biosciences Limited in the global market cap rankings as of September 19, 2026. Review Hester Biosciences Limited (HESTERBIO) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Hester Biosciences Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Hester Biosciences Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Hester Biosciences Limited's market cap moved from $48.98 Million to $ 201.99 Million, with a yearly change of 12.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs201.99 Million | +37.25% |
| 2025 | Rs147.17 Million | -33.33% |
| 2024 | Rs220.74 Million | +64.98% |
| 2023 | Rs133.80 Million | -18.25% |
| 2022 | Rs163.67 Million | -28.92% |
| 2021 | Rs230.27 Million | +48.81% |
| 2020 | Rs154.74 Million | +18.34% |
| 2019 | Rs130.76 Million | +28.91% |
| 2018 | Rs101.44 Million | -38.64% |
| 2017 | Rs165.31 Million | +160.92% |
| 2016 | Rs63.36 Million | +29.35% |
| 2015 | Rs48.98 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Hester Biosciences Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $201.99 Million USD |
| MoneyControl | $201.99 Million USD |
| MarketWatch | $201.99 Million USD |
| marketcap.company | $201.99 Million USD |
| Reuters | $201.99 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hester Biosciences Limited
Hester Biosciences Limited manufactures and trades in veterinary vaccines and animal health products in India and internationally. It operates through the Poultry Healthcare and Animal Healthcare segments. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal, fowl pox, marek's disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl… Read more